PI
AGIO icon

Pennant Investors’s Agios Pharmaceuticals AGIO Stock Holding History

Pennant Investors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,100
Closed -$651K – 17
2024
Q2 		$651K Hold
15,100
– – 0.17% 21
2024
Q1 		$442K Hold
15,100
– – 0.11% 26
2023
Q4 		$336K Buy
+15,100
New +$338K 0.07% 33

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Pennant Investors's AGIO Position: Q3 2024 in Review

Pennant Investors sold out of Agios Pharmaceuticals (AGIO) in Q3 2024, closing a stake of 15,100 shares — an estimated $651K sold.

Pennant Investors first reported a position in AGIO in Q4 2023 and held it in 3 quarters. The position peaked at $651K in Q2 2024. 208 funds tracked by Wall St. Rank hold AGIO as of Q3 2024.

  • Pennant Investors reported no remaining Agios Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pennant Investors sold 15,100 Agios Pharmaceuticals shares in Q3 2024, an estimated $651K.
  • Pennant Investors first reported a position in Agios Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Pennant Investors's Agios Pharmaceuticals position peaked at $651K in Q2 2024.
  • 208 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2024.

Based on Pennant Investors's 13F filing for Q3 2024, filed 14 Nov 2024.